Navigation Links
Dan Broderick Joins Prolog Ventures as Partner

ST. LOUIS, Sept. 12 /PRNewswire/ -- Prolog Ventures, a venture capital firm specializing in life science investments, today announced that Dan Broderick has joined the firm as its fourth partner. Broderick brings more than 20 years of experience in early-stage investing, venture fund management, and technology commercialization.

Before coming to Prolog, Broderick was a managing director at Mason Wells in Milwaukee, WI, where he served on its board of directors and management committee and managed the Mason Wells Biomedical Fund -- the firm's first venture capital fund. Prior to this, he spent 18 years at the Mayo Clinic in Rochester, MN, where he served as director of technology commercialization for 12 years and co-launched the clinic's corporate venture capital fund.

"Dan's extensive industry experience and deal flow connections further strengthen Prolog's expertise in early-stage life science investing," said Ilya Nykin, managing director of Prolog. "He was involved in the creation, financing, and growth of more than 20 venture-backed companies in Prolog's core areas of focus, most of them early-stage. Having Dan on Prolog's team is a great boost to our mission of translating life science breakthroughs into successful ventures."

Broderick's professional accomplishments have prompted a number of prominent industry boards and advisory panels to seek his involvement. He is a member of the board of directors of the National Venture Capital Association and the chair of its Research Committee; a trustee of both the Medical College of Wisconsin and the University of Wisconsin-Milwaukee Research Foundations; a member of the University of Minnesota Business Development Advisory Board; and a charter member of the venture capital advisory board of BioGenerator, a St. Louis nonprofit seed-capital investment fund.

"Not only is Dan an astute investor, but he is also a long-time colleague. We have an excellent track record of working together," said Greg Johnson, managing director of Prolog. "I met Dan 15 years ago, and over the years, we've collaborated on a number of investment opportunities. Our relationship expanded further in 2002 when we co-founded the Mid America Healthcare Investor Network (MHIN), an organization of more than 50 venture capital funds that focus on life science opportunities." MHIN is now recognized as one of the most active and productive venture capital associations in the country.

It was through MHIN that Broderick developed a close rapport with Prolog's other partners -- Ilya Nykin and Brian Clevinger. After Broderick's fund invested in ZyStor Therapeutics, one of the most promising ventures in Prolog's portfolio, he joined Clevinger on the company's board of directors. The two also have served together at several industry organizations including BioGenerator, InvestMidwest, and BIO Mid-America Venture Forum.

"I was attracted to Prolog because it has one of the most innovative and effective investment teams in the venture capital business," said Broderick. "I especially admire this firm for being committed since inception to balancing traditional healthcare investing with focused and resourceful pursuit of opportunities in emerging areas of life science. I am convinced this investment approach is the wave of the future and am excited to help the firm build on its early leadership position."

Prolog is a venture capital firm specializing in life science investing. Since its launch in 2001, Prolog has financed more than 20 early-stage companies. The firm is managed by a team of professionals with extensive experience as both investors and entrepreneurs. Prolog focuses on traditional healthcare opportunities as well as emerging areas - such as nutrition, wellness, plant science, and enabling platforms - in which it has built one of the largest portfolios in the country. For more information, visit

SOURCE Prolog Ventures
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Visions: Broderick says Wisconsin should be in top third in venture capital
2. Chemical-petroleum executive joins Virent Energy board
3. Schneider National exec joins TrafficCast board
4. Doyle joins governors in support of stem cell bill
5. Genomics researcher Hood joins NimbleGen board
6. Fergus joins Baird Venture Partners, Caden Bio
7. Meier joins Broadlook Technologies as COO
8. Prodesse joins forces with Invitrogen
9. Wisconsin joins price-fixing suit vs. D-RAM makers
10. Napier joins board of Third Wave Technologies
11. Schmidt rejoins Renaissance Learning
Post Your Comments:
(Date:6/23/2016)... 23, 2016 A person commits a crime, and ... to track the criminal down. An outbreak of ... Drug Administration (FDA) uses DNA evidence to track down the ... Sound far-fetched? It,s not. The FDA has increasingly used a ... of foodborne illnesses. Put as simply as possible, whole genome ...
(Date:6/23/2016)... , June, 23, 2016  The Biodesign Challenge (BDC), ... new ways to harness living systems and biotechnology, announced ... (MoMA) in New York City . ... participating students, showcased projects at MoMA,s Celeste Bartos Theater ... Antonelli , MoMA,s senior curator of architecture and design, ...
(Date:6/23/2016)... (PRWEB) , ... June 23, 2016 , ... In a ... Hospital in Denmark detail how a patient who developed lymphedema after being treated for ... The results could change the paradigm for dealing with this debilitating, frequent side effect ...
(Date:6/23/2016)... On Wednesday, June 22, 2016, the ... the Dow Jones Industrial Average edged 0.27% lower to finish ... 0.17%. has initiated coverage on the following equities: Infinity ... NKTR ), Aralez Pharmaceuticals Inc. (NASDAQ: ... ). Learn more about these stocks by accessing their free ...
Breaking Biology Technology:
(Date:5/9/2016)... DUBAI , UAE, May 9, 2016 ... choice when it comes to expanding freedom for high ... Even in today,s globally connected world, there ... online conferencing system could ever duplicate sealing your deal ... are obtaining second passports by taking advantage of citizenship ...
(Date:4/28/2016)... , April 28, 2016 First quarter ... (139.9), up 966% compared with the first quarter of 2015 ... totaled SEK 589.1 M (loss: 18.8) and the operating margin was ... (loss: 0.32) Cash flow from operations was SEK 249.9 ... 2016 revenue guidance is unchanged, SEK 7,000-8,500 M. The ...
(Date:4/19/2016)... The new GEZE SecuLogic access ... "all-in-one" system solution for all door components. It can ... door interface with integration authorization management system, and thus ... minimal dimensions of the access control and the optimum ... offer considerable freedom of design with regard to the ...
Breaking Biology News(10 mins):